Mark W. Tyndall mostly deals with Substance abuse, Cohort, Acquired immunodeficiency syndrome, Cohort study and SAFER. His Substance abuse study combines topics from a wide range of disciplines, such as Odds ratio, Surgery, Psychological intervention and Drug. The various areas that Mark W. Tyndall examines in his Cohort study include Condom, Psychiatry, Heroin and Emergency medicine.
His Acquired immunodeficiency syndrome research is multidisciplinary, incorporating elements of Demography, Immunology, Internal medicine, Risk factor and Hazard ratio. In Cohort study, Mark W. Tyndall works on issues like Methadone, which are connected to Speedball and Polysubstance dependence. His biological study spans a wide range of topics, including Social policy, Environmental health, Medical emergency, Social work and Public health.
His main research concerns Cohort, Internal medicine, Acquired immunodeficiency syndrome, Cohort study and Public health. His Cohort research is multidisciplinary, relying on both Odds ratio, Surgery, Hepatitis C virus, Hepatitis C and Hepatitis. His studies deal with areas such as Demography, Epidemiology and Risk factor as well as Acquired immunodeficiency syndrome.
His Cohort study research includes themes of Prospective cohort study and Substance abuse. His work in Substance abuse addresses issues such as Drug, which are connected to fields such as Syringe. His work carried out in the field of Public health brings together such families of science as Psychiatry, Family medicine and Environmental health.
His scientific interests lie mostly in Cohort, Hepatitis C, Internal medicine, Hepatitis and Hepatitis C virus. His work deals with themes such as Demography, Medical prescription, Prescription drug, Large population and Direct acting, which intersect with Cohort. Demography and Public health are commonly linked in his work.
His Hepatitis C study integrates concerns from other disciplines, such as Coinfection, Hepatitis B and Cohort study. Mark W. Tyndall interconnects Ledipasvir, Oncology and Sofosbuvir in the investigation of issues within Internal medicine. His Hepatitis research integrates issues from Epidemiology, Incidence, Lower risk, Hazard ratio and Pediatrics.
His primary areas of study are Hepatitis C, Cohort, Hepatitis, Public health and Hepatitis C virus. The study incorporates disciplines such as Immunology, Medical prescription and Cohort study in addition to Cohort. His studies examine the connections between Cohort study and genetics, as well as such issues in Lower risk, with regards to Substance abuse, Proportional hazards model and Hazard ratio.
His study in Hepatitis is interdisciplinary in nature, drawing from both Hepatitis B and Epidemiology. His research integrates issues of Psychiatry and MEDLINE in his study of Public health. His Internal medicine research incorporates themes from Gastroenterology and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review
Bradley M Mathers;Louisa Degenhardt;Louisa Degenhardt;Benjamin Phillips;Lucas Wiessing.
The Lancet (2008)
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
Julio S. G. Montaner;Robert Hogg;Evan Wood;Thomas Kerr.
The Lancet (2006)
Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work
Kate Shannon;Thomas Kerr;Shari Allinott;Jill Chettiar.
Social Science & Medicine (2008)
Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic.
Mark W Tyndall;Sue Currie;Patricia Spittal;Kathy Li.
Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers.
Kate Shannon;Thomas Kerr;Steffanie A. Strathdee;Jean Shoveller.
Structural and Environmental Barriers to Condom Use Negotiation With Clients Among Female Sex Workers: Implications for HIV-Prevention Strategies and Policy
Kate Shannon;Steffanie A. Strathdee;Jean Shoveller;Melanie Rusch.
American Journal of Public Health (2009)
Safer injection facility use and syringe sharing in injection drug users
Thomas Kerr;Thomas Kerr;Mark Tyndall;Mark Tyndall;Kathy Li;Kathy Li;Julio Montaner;Julio Montaner.
The Lancet (2005)
Hospital utilization and costs in a cohort of injection drug users
Anita Palepu;Mark W. Tyndall;Hector Leon;Jennifer Muller.
Canadian Medical Association Journal (2001)
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users
Evan Wood;Thomas Kerr;Will Small;Kathy Li.
Canadian Medical Association Journal (2004)
Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection
David M. Patrick;Mark W. Tyndall;Peter G.A. Cornelisse;Kathy Li.
Canadian Medical Association Journal (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: